Partner Dan Altman was quoted in “SCOTUS’ denial of certiorari in Idenix v Gilead poses especially difficult IP questions for universities and small biotechs” an article published by IAM-Media.
Excerpt: “What’s more, organizations that are under pressure to file early are especially badly affected by the current caselaw, comments Dan Altman of Knobbe Martens. “Universities tend to have to file at a very early stage, because their professors want to publish their inventions,” he notes. Small biotechs could suffer from similar difficulties, he adds, especially if not partnered with a Big Pharma.”
Read the full article here >> (Subscription Required)
